• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Barnwell Industries, Inc. Reaches Cooperation and Support Agreement With its Largest Stockholders

    1/23/23 6:00:00 AM ET
    $BMRA
    $BRN
    $LMB
    $MINM
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Oil & Gas Production
    Energy
    Get the next $BMRA alert in real time by email

    HONOLULU, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Barnwell Industries, Inc. (NYSE-American: BRN) ("Barnwell" or the "Company") announce today that it has entered into a cooperation and support agreement (the "Agreement") with its two largest stockholders, Alexander C. Kinzler, who beneficially owns approximately 9.3% of the Company's outstanding common stock, and MRMP-Managers LLC, Ned L. Sherwood Revocable Trust, and Ned L. Sherwood (collectively, the "MRMP Stockholders"), who beneficially own approximately 19.6% of the Company's outstanding common stock. The Agreement extends for two years the standstill terms of the previous agreement entered into with the MRMP Stockholders in 2021, ending the potential of a proxy contest at the 2023 annual meeting of stockholders (the "2023 Annual Meeting").

    Pursuant to the terms of the Agreement, among other things, the Company has agreed to promptly appoint Joshua S. Horowitz and Laurance Narbut to serve on its Board of Directors (the "Board"), subject to certain customary board procedures. The Board has determined that each of Mr. Horowitz and Narbut are independent under applicable NYSE rules and regulations.

    Mr. Horowitz is a Portfolio Manager at Palm Management (US) LLC. He has held senior positions at Inverlochy Capital, an asset management firm, and Berggruen Holdings, the family office of Nicolas Berggruen. He began his career at Crossway Partners, a value strategy investment partnership. Mr. Horowitz holds a BS in Management, magna cum laude, from Binghamton University and also studied at the Bath School of Management in the United Kingdom. Mr. Horowitz previously served as a Director of The Lincoln General Insurance Company (private), as well as 1347 Capital Corp (NASDAQ:TFSC), and is currently a Director and Chair of the Finance Committee of Limbach Holdings (NASDAQ:LMB), a $500m mechanical engineering concern. He was formerly on the Board of 1347 Property Insurance Holdings, Inc. (NASDAQ:PIH) and Minim, Inc. (NASDAQ:MINM), and Interim Chairman of the Board of Birner Dental Management Services, Inc. (OTC:BDMS), where he led the Company's sale to Mid Atlantic Dental Partners. Mr. Horowitz also was a Board Observer at Biomerica, Inc. (NASDAQ:BMRA).

    Mr. Narbut is the founder and Managing Partner of Acceleration Resources. Mr. Narbut has held senior positions at Passport Capital, Richmond Financial, SUN Capital Partners, Credit Suisse First Boston, and Parthenon Group. At Passport Capital, Mr. Narbut was a portfolio manager for the energy strategy, investing across multiple funds and focused on upstream oil & gas and energy service investments. Mr. Narbut attended Harvard Business School and the University of Pennsylvania

    Pursuant to the terms of the Agreement, the Company has agreed to nominate Mr. Kinzler, Barnwell's CEO and President, Kenneth Grossman, Douglas Woodrum, and Messrs. Horowitz and Narbut as candidates for election to the Board at the 2023 Annual Meeting and the 2024 annual meeting of stockholders (the "2024 Annual Meeting") and Mr. Kinzler and the MRMP Stockholders have agreed to vote their respective shares of common stock of the Company in favor of the election of the Company's slate at the 2023 Annual Meeting and 2024 Annual Meeting.

    Pursuant to the terms of the Agreement, the Company also has terminated the previously enacted Tax Benefits Preservation Plan, although the MRMP Stockholders have agreed to limit their beneficial and economic ownership of the Company to 28% of the outstanding common stock of the Company for the next 12 months and 30% for the subsequent 12-month period.

    Mr. Grossman, the newly appointed Chairman of the Board, said, "We are gratified to have found common ground and alignment with our two largest stockholders to avoid the distraction and cost of another proxy contest. In addition to demonstrating the commitment of the incoming Board to act in the long-term interests of all stockholders, I believe this extension of the previous cooperation and support agreement continues the significant progress the Company has made over the past several years toward strengthening and streamlining its governance and operations."

    Mr. Sherwood said "I am pleased that agreement has been reached. I am positive that the prospective new Board members along with the remaining members will add new dynamism and excellent leadership in the future. Eliminating the significant distractions and overhead costs related to our past discord should benefit the Company and all stockholders."

    Additional Information.

    Barnwell intends to file a proxy statement and proxy card with United States Securities and Exchange Commission (the "SEC") in connection with its solicitation of proxies for its 2023 Annual Meeting. Details concerning the nominees of Barnwell's Board of Directors for election at the 2023 Annual Meeting will be included in the proxy statement. BARNWELL STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE DEFINITIVE PROXY STATEMENT (AND ANY AMENDMENTS AND SUPPLEMENTS THERETO) AND ACCOMPANYING PROXY CARD WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders may obtain the proxy statement, any amendments or supplements to the proxy statement and other documents as and when filed by Barnwell with the SEC without charge from the SEC's website at www.sec.gov.

    Barnwell, its directors and certain of its executive officers may be deemed to be participants in connection with the solicitation of proxies from Barnwell's stockholders in connection with the matters to be considered at the 2023 Annual Meeting. Information regarding the ownership of Barnwell's directors and executive officers in Barnwell stock is included in their SEC filings on Forms 3, 4, and 5, which can be found through the SEC's website at www.sec.gov. Information also can be found in Barnwell's other SEC filings. More detailed and updated information regarding the identity of potential participants, and their direct or indirect interests, by security holdings or otherwise, will be set forth in the proxy statement and other materials to be filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

    The information contained in this press release contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. A forward-looking statement is one which is based on current expectations of future events or conditions and does not relate to historical or current facts. These statements include various estimates, forecasts, projections of Barnwell's future performance, statements of Barnwell's plans and objectives, and other similar statements. Forward-looking statements include phrases such as "expects," "anticipates," "intends," "plans," "believes," "predicts," "estimates," "assumes," "projects," "may," "will," "will be," "should," or similar expressions. Although Barnwell believes that its current expectations are based on reasonable assumptions, it cannot assure that the expectations contained in such forward-looking statements will be achieved. Forward-looking statements involve risks, uncertainties and assumptions which could cause actual results to differ materially from those contained in such statements. The risks, uncertainties and other factors that might cause actual results to differ materially from Barnwell's expectations are set forth in the "Forward-Looking Statements," "Risk Factors" and other sections of Barnwell's annual report on Form 10-K for the last fiscal year and Barnwell's other filings with the Securities and Exchange Commission. Investors should not place undue reliance on the forward-looking statements contained in this press release, as they speak only as of the date of this press release, and Barnwell expressly disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statements contained herein.

    CONTACT:Alexander C. Kinzler
     Chief Executive Officer and President
      
     Russell M. Gifford
     Executive Vice President and Chief Financial Officer
     Tel: (808) 531-8400

     



    Primary Logo

    Get the next $BMRA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMRA
    $BRN
    $LMB
    $MINM

    CompanyDatePrice TargetRatingAnalyst
    Limbach Holdings Inc.
    $LMB
    11/15/2024$108.00Buy
    Stifel
    Limbach Holdings Inc.
    $LMB
    11/22/2021$15.00Buy
    EF Hutton
    Minim Inc.
    $MINM
    10/25/2021$3.00Outperform
    Northland Capital Markets
    Minim Inc.
    $MINM
    8/6/2021$4.00Buy
    B. Riley Securities
    More analyst ratings

    $BMRA
    $BRN
    $LMB
    $MINM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Limbach with a new price target

    Stifel initiated coverage of Limbach with a rating of Buy and set a new price target of $108.00

    11/15/24 8:13:18 AM ET
    $LMB
    Engineering & Construction
    Consumer Discretionary

    EF Hutton initiated coverage on Limbach Holdings with a new price target

    EF Hutton initiated coverage of Limbach Holdings with a rating of Buy and set a new price target of $15.00

    11/22/21 8:34:12 AM ET
    $LMB
    Engineering & Construction
    Consumer Discretionary

    Northland Capital Markets initiated coverage on Minim with a new price target

    Northland Capital Markets initiated coverage of Minim with a rating of Outperform and set a new price target of $3.00

    10/25/21 8:49:12 AM ET
    $MINM
    Telecommunications Equipment
    Utilities

    $BMRA
    $BRN
    $LMB
    $MINM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica's inFoods® IBS Test in the U.S.

    - Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation's Most Trusted Health Care Distributors- Relationship Marks a Key Milestone in Biomerica's Commercialization Strategy IRVINE, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company, announced today a marketing services arrangement with Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, to market Biomerica's inFoods® Irritable Bowel Syndrome (IBS) test in the United States, excluding New York State. Henry Schein's powerful nationwide distribution network, comprised of m

    10/16/25 8:19:00 AM ET
    $BMRA
    $HSIC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical Specialities

    Biomerica Reports First Quarter Fiscal 2026 Financial Results

    Reported Improved Gross Margin from Contribution from Higher-Margin Product MixOperating Expenses Continued to Decline Compared to the First Quarter of the Prior Fiscal Year, Reflecting the Company's Ongoing Focus on Cost Reduction and Operational EfficiencyEarnings per Share $0.00, Compared to a Net Loss of $0.08 per Share in the First Quarter of the Prior Fiscal Year. IRVINE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), ("Biomerica" or the "Company") a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the first quarter ended August 31, 2025. Key Highlights: inFoods® IBS receives P

    10/15/25 9:27:00 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Limbach to Announce Third Quarter 2025 Results

    Limbach Holdings, Inc. (NASDAQ:LMB) ("Limbach" or the "Company"), a building systems solutions firm that partners with building owners and facilities managers who have mission-critical mechanical, electrical, and plumbing infrastructure, today announced that it will release its third quarter 2025 financial results after the stock market closes on Tuesday, November 4, 2025. The Company will also host a conference call for analysts the following morning at 9:00 a.m. ET. Conference Call Details Date: Wednesday, November 5, 2025 Time: 9:00 a.m. ET Participant Dial-In Numbers: Domestic Callers: (877) 407-6176 International Callers: +1 (201) 689-8451 Access By Webcast The call wil

    10/15/25 9:00:00 AM ET
    $LMB
    Engineering & Construction
    Consumer Discretionary

    $BMRA
    $BRN
    $LMB
    $MINM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Horowitz Joshua was granted 44,445 shares, increasing direct ownership by 33% to 178,312 units (SEC Form 4)

    4 - BARNWELL INDUSTRIES INC (0000010048) (Issuer)

    10/10/25 5:12:11 PM ET
    $BRN
    Oil & Gas Production
    Energy

    Director Grossman Kenneth S was granted 44,445 shares, increasing direct ownership by 27% to 212,040 units (SEC Form 4)

    4 - BARNWELL INDUSTRIES INC (0000010048) (Issuer)

    10/10/25 5:11:25 PM ET
    $BRN
    Oil & Gas Production
    Energy

    Director Mcpherson Philip James was granted 44,445 shares (SEC Form 4)

    4 - BARNWELL INDUSTRIES INC (0000010048) (Issuer)

    10/10/25 5:08:50 PM ET
    $BRN
    Oil & Gas Production
    Energy

    $BMRA
    $BRN
    $LMB
    $MINM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gaboury David Richard bought $148,400 worth of shares (1,400 units at $106.00), increasing direct ownership by 48% to 4,297 units (SEC Form 4)

    4 - Limbach Holdings, Inc. (0001606163) (Issuer)

    8/13/25 4:12:30 PM ET
    $LMB
    Engineering & Construction
    Consumer Discretionary

    Chief Financial Officer Yu Cao bought $2,600,000 worth of shares (1,585,366 units at $1.64) (SEC Form 4)

    4 - FiEE, Inc. (0001467761) (Issuer)

    5/13/25 4:19:07 PM ET
    $MINM
    Telecommunications Equipment
    Utilities

    Director Bin Hu bought $1,400,001 worth of shares (853,659 units at $1.64) (SEC Form 4)

    4 - FiEE, Inc. (0001467761) (Issuer)

    5/13/25 4:16:26 PM ET
    $MINM
    Telecommunications Equipment
    Utilities

    $BMRA
    $BRN
    $LMB
    $MINM
    SEC Filings

    View All

    SEC Form DEFA14A filed by Biomerica Inc.

    DEFA14A - BIOMERICA INC (0000073290) (Filer)

    10/23/25 4:15:04 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form DEF 14A filed by Biomerica Inc.

    DEF 14A - BIOMERICA INC (0000073290) (Filer)

    10/20/25 5:05:17 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-Q filed by Biomerica Inc.

    10-Q - BIOMERICA INC (0000073290) (Filer)

    10/14/25 5:11:06 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $BMRA
    $BRN
    $LMB
    $MINM
    Leadership Updates

    Live Leadership Updates

    View All

    Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors

    Brings decades of leadership in laboratory testing, clinical diagnostics, payor strategy, and sales growth Extensive track record in commercializing advanced laboratory testing and insurer strategies IRVINE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, today announced the appointment of Gary Huff to its Board of Directors as an independent board member. Mr. Huff brings decades of leadership experience in the diagnostics and healthcare services industry, including serving as Chief Executive Officer of LabCorp Diagnostics, one of the world's largest clinical laboratories. Mr. Huff is a hands-on, inspirational,

    10/8/25 8:19:00 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica's Team as Chief Commercial Officer

    Brings 20+ years of revenue growth leadership in laboratory testing, clinical diagnostics and global expansionLed successful organizational turnarounds and growth strategies at both Boston Heart Diagnostics and Genova DiagnosticsExtensive track record in commercializing advanced laboratory testing, driving growth and payer strategies IRVINE, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Scott Madel as Chief Commercial Officer. Scott brings more than two decades of cross-functional expertise in healthcare, diagnostics, commercialization, and pa

    6/26/25 8:19:00 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair

    Mr. Chin brings over 20 years of financial experience across public and private healthcare organizationsMr. Chin currently serves as CFO of Akido Labs where he successfully helped raise $60 million in a recent financingMr. Chin's appointment strengthens Biomerica's corporate governance and financial oversight as Biomerica scales commercialization efforts IRVINE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products, today announced that Eric B. Chin has been appointed to the Company's Board of Directors, effective June 4, 2025. Mr. Chin will serve

    6/6/25 9:30:00 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $BMRA
    $BRN
    $LMB
    $MINM
    Financials

    Live finance-specific insights

    View All

    Limbach to Announce Third Quarter 2025 Results

    Limbach Holdings, Inc. (NASDAQ:LMB) ("Limbach" or the "Company"), a building systems solutions firm that partners with building owners and facilities managers who have mission-critical mechanical, electrical, and plumbing infrastructure, today announced that it will release its third quarter 2025 financial results after the stock market closes on Tuesday, November 4, 2025. The Company will also host a conference call for analysts the following morning at 9:00 a.m. ET. Conference Call Details Date: Wednesday, November 5, 2025 Time: 9:00 a.m. ET Participant Dial-In Numbers: Domestic Callers: (877) 407-6176 International Callers: +1 (201) 689-8451 Access By Webcast The call wil

    10/15/25 9:00:00 AM ET
    $LMB
    Engineering & Construction
    Consumer Discretionary

    Limbach Holdings, Inc. Reports Second Quarter 2025 Results

    Delivered Q2 Net Income of $7.8 million and Adjusted EBITDA of $17.9 million Increases Full Year 2025 Revenue Guidance to $650 million to $680 million and Adjusted EBITDA to $80 million to $86 million Limbach Holdings, Inc. (NASDAQ:LMB) ("Limbach" or the "Company") today announced its financial results for the quarter ended June 30, 2025. Second Quarter 2025 Highlights Compared to Second Quarter 2024 Total revenue was $142.2 million, an increase of 16.4% from $122.2 million Net income of $7.8 million, or $0.64 per diluted share, compared to $6.0 million, or $0.50 per diluted share Adjusted net income of $11.3 million, or $0.93 per adjusted diluted earnings per share, compared

    8/5/25 4:05:00 PM ET
    $LMB
    Engineering & Construction
    Consumer Discretionary

    Limbach to Announce Second Quarter 2025 Results

    Limbach Holdings, Inc. (NASDAQ:LMB) ("Limbach" or the "Company"), a building systems solutions firm that partners with building owners and facilities managers who have mission-critical mechanical, electrical, and plumbing infrastructure, today announced that it will release its second quarter 2025 financial results after the stock market closes on Tuesday, August 5, 2025. The Company will also host a conference call for analysts the following morning at 9:00 a.m. ET. Conference Call Details Date: Wednesday, August 6, 2025 Time: 9:00 a.m. ET Participant Dial-In Numbers: Domestic Callers: (877) 407-6176 International Callers: +1 (201) 689-8451 Access By Webcast The call will b

    7/22/25 4:16:00 PM ET
    $LMB
    Engineering & Construction
    Consumer Discretionary

    $BMRA
    $BRN
    $LMB
    $MINM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Barnwell Industries Inc.

    SC 13D/A - BARNWELL INDUSTRIES INC (0000010048) (Subject)

    12/6/24 11:27:43 AM ET
    $BRN
    Oil & Gas Production
    Energy

    Amendment: SEC Form SC 13D/A filed by Minim Inc.

    SC 13D/A - MINIM, INC. (0001467761) (Subject)

    11/15/24 5:00:07 PM ET
    $MINM
    Telecommunications Equipment
    Utilities

    Amendment: SEC Form SC 13G/A filed by Biomerica Inc.

    SC 13G/A - BIOMERICA INC (0000073290) (Subject)

    11/14/24 4:19:51 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care